Diarrhea Management in Celiac Disease

Introduction to Diarrhea Management

• Diarrhea management in celiac disease involves a comprehensive approach, including dietary compliance, screening for other causes of diarrhea, and treatment of complications, as recommended by the American Gastroenterological Association (AGA) 1, 2

Dietary Compliance and Adherence

• Verify strict adherence to a gluten-free diet, as ongoing gluten exposure can cause persistent symptoms, with a strong recommendation based on moderate quality evidence 1
• Consider testing for immunogenic peptides in stool or urine to confirm adherence, as suggested by the AGA 1

Bile Acid Malabsorption

• Consider bile acid sequestrants such as cholestyramine if symptoms suggest bile acid malabsorption, with a conditional recommendation based on moderate quality evidence 3
• Administer bile acid sequestrants at least 1 hour before or 4-6 hours after other medications to avoid drug interactions, as recommended by the European Society of Gastrointestinal Endoscopy 3

Screening for Other Causes of Diarrhea

• Screen for other causes of persistent diarrhea, including small intestinal bacterial overgrowth (SIBO), pancreatic insufficiency, lactose or fructose intolerance, and inflammatory bowel disease, as recommended by the AGA 1
• Celiac disease screening is essential, as it is present in 5-7% of microscopic colitis patients, according to the European Society of Gastrointestinal Endoscopy 4

Microscopic Colitis Diagnosis and Treatment

• Obtain biopsies from multiple segments of the colon during diagnosis to ensure accurate diagnosis of microscopic colitis, with a strong recommendation based on moderate quality evidence, as suggested by the AGA 2
• Identify and discontinue medications associated with microscopic colitis, including statins, NSAIDs, PPIs, and SSRIs, with a strong recommendation based on moderate quality evidence, as recommended by the AGA 2, 5
• Budesonide is recommended as the first-line treatment for induction of clinical remission in symptomatic microscopic colitis, with high-quality evidence, due to its low risk of serious adverse events and convenient once-daily dosing, as recommended by the AGA 2
• Alternative treatments, including mesalamine, bismuth salicylate, and prednisolone/prednisone, may be considered if budesonide is not feasible, with conditional recommendations and varying levels of evidence, as suggested by the AGA 2

Treatment Regimens and Monitoring

• Budesonide is recommended at a dose of 9 mg daily for 8 weeks, with a strong recommendation based on moderate quality evidence, and is the first-line treatment for symptomatic microscopic colitis, with strong evidence supporting its effectiveness for both induction and maintenance therapy, as recommended by the AGA 2
• Bone health monitoring is essential for patients on long-term budesonide therapy, with a conditional recommendation based on moderate quality evidence, according to the AGA, and discontinuation of budesonide should be considered after 6-12 months, with monitoring for bone loss with prolonged use 2
• Bile acid diarrhea can be managed with bile acid sequestrants, such as cholestyramine, with a conditional recommendation based on moderate quality evidence, according to the European Society of Gastrointestinal Endoscopy 4

Risk Factor Assessment and Prevention

• Assessing modifiable risk factors, especially cigarette smoking and alcohol consumption, is crucial, as stated by the American Cancer Society and the National Institute on Alcohol Abuse and Alcoholism 4
• Common pitfalls include failing to obtain biopsies from multiple segments of the colon during diagnosis, overlooking associated conditions like celiac disease, and neglecting bone health monitoring in patients on long-term budesonide therapy, with conditional recommendations based on moderate quality evidence, according to the AGA 2

2